How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study

Implementation Science

Geoffrey A Porter⁵  Eva Grunfeld⁶  Daniel Rayson⁴  Paul Johnson¹  Gordon Buduhan¹  Joan Sargeant²  Cynthia Kendell³  Robin Urquhart³ 

[1] Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada;Continuing Medical Education, Dalhousie University, Halifax, Nova Scotia, Canada;Cancer Outcomes Research Program, Cancer Care Nova Scotia, Halifax, Nova Scotia, Canada;Division of Medical Oncology, Dalhousie University, Halifax, Nova Scotia, Canada;Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada;Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada

关键词: Grounded theory;    Qualitative methods;    Referral rates;    Surgeon;    Cancer;   

Others  :  813888
DOI  :  10.1186/1748-5908-7-102

 received in 2012-09-22, accepted in 2012-10-22,  发布年份 2012

【 摘 要 】

Background

Non-small cell lung cancer, breast cancer, and colorectal cancer are commonly diagnosed cancers in Canada. Patients diagnosed with early-stage non-small cell lung, breast, or colorectal cancer represent potentially curable populations. For these patients, surgery is the primary mode of treatment, with (neo)adjuvant therapies (e.g., chemotherapy, radiotherapy) recommended according to disease stage. Data from our research in Nova Scotia, as well as others’, demonstrate that a substantial proportion of non-small cell lung cancer and colorectal cancer patients, for whom practice guidelines recommend (neo)adjuvant therapy, are not referred for an oncologist consultation. Conversely, surveillance data and clinical experience suggest that breast cancer patients have much higher referral rates. Since surgery is the primary treatment, the surgeon plays a major role in referring patients to oncologists. Thus, an improved understanding of how surgeons make decisions related to oncology services is important to developing strategies to optimize referral rates. Few studies have examined decision making for (neo)adjuvant therapy from the perspective of the cancer surgeon. This study will use qualitative methods to examine decision-making processes related to referral to oncology services for individuals diagnosed with potentially curable non-small cell lung, breast, or colorectal cancer.

Methods

A qualitative study will be conducted, guided by the principles of grounded theory. The study design is informed by our ongoing research, as well as a model of access to health services. The method of data collection will be in-depth, semi structured interviews. We will attempt to recruit all lung, breast, and/or colorectal cancer surgeons in Nova Scotia (n ≈ 42), with the aim of interviewing a minimum of 34 surgeons. Interviews will be audiotaped and transcribed verbatim. Data will be collected and analyzed concurrently, with two investigators independently coding and analyzing the data. Analysis will involve an inductive, grounded approach using constant comparative analysis.

Discussion

The primary outcomes will be (1) identification of the patient, surgeon, institutional, and health-system factors that influence surgeons’ decisions to refer non-small cell lung, breast, and colorectal cancer patients to oncology services when consideration for (neo)adjuvant therapy is recommended and (2) identification of potential strategies that could optimize referral to oncology for appropriate individuals.

【 授权许可】

   
2012 Urquhart et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Canadian Cancer Society’s Steering Committee: Canadian Cancer Statistics 2011. Canadian Cancer Society, Toronto, ON; 2011.
• [2]NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer JAMA 1990, 264(11):1444-1450.
• [3]Figueredo A, Germond C, Taylor B, Maroun J, Agboola O, Wong R, Zwaal C, Miccucci S, for the Gastrointestinal Cancer Disease Site Group: Post-operative adjuvant radiotherapy or chemotherapy for resected stage II or III rectal cancer. Curr Oncol 2000, 7:37-51.
• [4]Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995, 333(22):1456-1461.
• [5]Birnie K, Robinson J: Helping patients with localized prostate cancer reach treatment decisions. Can Fam Phys 2010, 56(2):137-141.
• [6]Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, International Adjuvant Lung Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350(4):351-360.
• [7]Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, et al.: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7(9):719-727.
• [8]Early Breast Cancer Trialists’ Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717.
• [9]Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ, QUASAR Collaborative Group: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370(9604):2020-2029.
• [10]Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345(15):1091-1097.
• [11]Strauss GM, Herndon J, Maddaus MA, Johnstone DW, Johnson EA, Watson DJ, Sugarbaker DJ, Schilsky RL, Green MR: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 2004, 22(14S):A7019.
• [12]Winton T, Livington R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, et al.: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005, 352(25):2589-2597.
• [13]Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ: Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007, 57(3):168-185.
• [14]Cancer Care Ontario: Breast Cancer Evidence-based Series (EBS) and Practice Guidelines (PG). 2012. Available at: https://www.cancercare.on.ca/toolbox/qualityguidelines/diseasesite/breast-ebs/ webcite
• [15]Cancer Care Ontario: Gastrointestinal Cancer Evidence-based Series (EBS) and Practice Guidelines (PG). 2012. Available at: https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10207 webcite
• [16]Cancer Care Ontario: Lung Cancer Evidence-based Series (EBS) and Practice Guidelines (PG). 2012. Available at: https://www.cancercare.on.ca/toolbox/qualityguidelines/diseasesite/lung-ebs/ webcite
• [17]Figueredo A, Fine S, Maroun J, Walker-Dilks C, Wong S: Adjuvant therapy for stage III colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev Control 1997, 1(4):314-319.
• [18]Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis PM, et al.: Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007, 25(34):5506-5518.
• [19]Wong R, Berry S, Spithoff K, Simunovic M, Chan K, Agboola O, Dingle B, Rumble RB, Cummings B, Gastrointestinal Cancer Disease Site Group: Preoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer: Guideline Recommendations. Program in Evidence-Base Care, Cancer Care Ontario, Hamilton, ON; 2008.
• [20]Younis T, Al-Fayea T, Virik K, Saint-Jacques N: Adjuvant chemotherapy uptake in non-small cell lung cancer. J Thor Oncol 2008, 3(11):1272-1278.
• [21]Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA: Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004, 1717(10):1189-1192.
• [22]Cree M, Tonita J, Turner D, Nugent Z, Alvi R, Barss R, King C, Winget M: Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004. Clin Colorectal Cancer 2009, 8(3):141-145.
• [23]Francke AL, Smith MC, de Veer AJ, Mistiaen P: Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Dec Mak 2008, 8:38. BioMed Central Full Text
• [24]Grunfeld E, Hodgson DC, Del Giudice E, Moineddin R: Population-based longitudinal study of follow-up care for breast cancer survivors. J Oncol Practice 2010, 6(4):174-181.
• [25]Latosinsky S, Fradette K, Lix L, Hildebrand K, Turner D: Canadian breast cancer guidelines: have they made a difference? CMAJ 2007, 176(6):771-776.
• [26]McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, Kerr EA: The quality of health care delivered to adults in the United States. N Engl J Med 2003, 348(26):2635-2645.
• [27]Winget M, Hossain S, Yasui Y, Scarfe A: Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment. Cancer 2010, 116(20):4849-4856.
• [28]Contandriopoulos D, Lemire M, Denis JL, Tremblay E: Knowledge exchange processes in organizations and policy arenas: a narrative systematic review of the literature. Milbank Q 2010, 88(4):444-483.
• [29]Davis D, Evans M, Jadad A, Perrier L, Rath D, Ryan D, Sibbald G, Straus S, Rappolt S, Wowk M, et al.: The case for knowledge translation: shortening the journey from evidence to effect. BMJ 2003, 327(7405):33-35.
• [30]Grol R, Bosch MC, Hulscher M, Eccles MP, Wensing M: Planning and studying improvement in patient care: the use of theoretical perspectives. Milbank Q 2007, 85(1):93-138.
• [31]Grol R, Grimshaw J: From best evidence to best practice: effective implementation of change in patients’ care. Lancet 2003, 362(9391):1225-1230.
• [32]Iles V, Sutherland K: Organizational change: A review for health care managers, professionals and researchers. National Health Service, London, UK; 2001. Available at: http://www.sdo.nihr.ac.uk/files/adhoc/change-management-review.pdf webcite
• [33]Kitson AL: The need for systems change: reflections on knowledge translation and organizational change. J Adv Nurs 2009, 65(1):217-228.
• [34]Kitson AL, Rycroft-Malone J, Harvey G, McCormack B, Seers K, Titchen A: Evaluating the successful implementation of evidence into practice using the PARiHS framework: theoretical and practical challenges. Implement Sci 2008, 3(1):1. BioMed Central Full Text
• [35]Kerba M, Miao Q, Zhang-Salomons J, Mackillop WJ: Defining the need for breast cancer radiotherapy in the general population: a criterion-based benchmarking approach. Clin Oncol (R Coll Radiol) 2007, 19(7):481-489.
• [36]Ong S, Watters JM, Grunfeld E, O’Rourke K: Predictors of referral for adjuvant therapy for colorectal cancer. Can J Surg 2005, 48(3):225-229.
• [37]Paszat LF, Groome PA, Mackillop WJ, Zhang-Salomons J, Schulze K, Holowaty E: Radiotherapy for breast cancer in Ontario: rate variation associated with region, age and income. Clin Invest Med 1998, 21(3):125-134.
• [38]Tyldesley S, Zhang-Salomons J, Groome PA, Zhou S, Schulze K, Paszat LF, Mackillop WJ: Association between age and the utilization of radiotherapy in Ontario. Int J Radiol Oncol Biol Phys 2000, 47(2):469-480.
• [39]Rayson D, Urquhart R, Cox M, Grunfeld E, Porter G: Adherence to clinical practice guidelines for adjuvant chemotherapy for colorectal cancer in a Canadian province: a population-based analysis. J Oncol Pract 2012, 8(4):253-259.
• [40]Hanna TP: A population-based study of factors affecting access to radiotherapy for endometrial cancer in Ontario. Queens University, Department of Community Health and Epidemiology; 2009.
• [41]Zhang-Salomons J, Fourodi F, Huang J, Mackillop WJ: Health system effects on the use of radiotherapy following surgery for breast cancer. Abstr Acad Health Serv Res Health Policy Meet 2002, 19:45.
• [42]Mackillop WJ, Groome PA, Zhang-Salomons JY, Zhou Y, Feldman-Stewart D, Paszat LF, Dixon P, Holowaty EJ, Cummings BJ: Does a centralized radiotherapy system provide adequate access to care? J Clin Oncol 1997, 15(3):1261-1271.
• [43]Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006, 24(25):4085-4091.
• [44]Zuckerman IH, Rapp T, Onukwugha E, Davidoff AJ, Choti MA, Gardner J, Seal B, Mullins CD: Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer. J Am Geriatr Soc 2009, 57(8):1403-1410.
• [45]Gagliardi A, Wright FC, Quan ML, McCready D: Evaluating the organization and delivery of breast cancer services: use of performance measures to identify knowledge gaps. Breast Cancer Res Treat 2007, 103(2):131-148.
• [46]Gagliardi AR, Simunovic M, Langer B, Stern H, Brown AD: Development of quality indicators for colorectal cancer surgery, using a 3-step modified Delphi approach. Can J Surg 2005, 48(6):441-452.
• [47]McGory ML, Shekelle PG, Yo CY: Development of quality indicators for patients undergoing colorectal cancer surgery. J Natl Cancer Inst 2006, 98(22):1623-1633.
• [48]Bouchard N, Laberge F, Raby B, Martin S, Lacasse Y: Adjuvant chemotherapy in resected lung cancer: two-year experience in a university hospital. Can Respir J 2008, 15(5):270-274.
• [49]Kassam F, Shepherd FA, Johnston M, Visbal A, Feld R, Darling G, Keshavjee S, Pierre A, Waddell T, Leighi NB: Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. J Thorac Oncol 2007, 2(1):39-43.
• [50]Jagsi R, Abrahamse P, Morrow M, Hamilton AS, Graff JJ, Katz SJ: Coordination of Breast Cancer Care Between Radiation Oncologists and Surgeons: A Survey Study. Int J Radiat Oncol Biol Phys 2012, 82(5):2072-2078.
• [51]Keating NL, Landrum MB, Klabunde CN, Fletcher RH, Rogers SO Jr, Doucette WR, Tisnado D: Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 2008, 26(15):2532-2537.
• [52]Schroen AT, Detterbeck FC, Crawford R, Rivera MP, Socinski MA: Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer. Chest 2000, 118(1):129-137.
• [53]Davidoff AJ, Rapp T, Onukwugha E, Zuckerman IH, Hanna N, Pandya N, Mullins CD: Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients, the role of the medical oncologist evaluation. Med Care 2009, 47(12):1229-1236.
• [54]Luo R, Giordano SH, Freeman JL, Zhang DD, Goodwin JS: Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer. Oncologist 2006, 11(9):1025-1033.
• [55]Luo R, Giordano SH, Zhang DD, Freeman J, Goodwin JS: The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist. Cancer 2007, 109(5):975-982.
• [56]Grunfeld E, Porter GA, Rayson D, Johnston G, Burge F, van Zanten S, Kisely S, Kephart G, Dewar R, Rheaume D, et al.: Towards measuring and improving access to quality cancer services in Nova Scotia. Canadian Institutes of Health Research (CIHR), Halifax, NS; 2007–2012.
• [57]Dunscombe P, Roberts G: Radiotherapy service delivery models for a dispersed patient population. Clin Oncol (R Coll Radiol) 2001, 13(1):29-37.
• [58]Matthews M, Basky G: Closer to home: the burden of out-of-pocket expenses on cancer patients in Newfoundland and Labrador. Memorial University of Newfoundland, St. John’s, NL; 2004.
• [59]Nattinger AB, Kneusel RT, Hoffmann RG, Gilligan MA: Relationship of distance from a radiotherapy facility and initial breast cancer treatment. J Natl Cancer Inst 2001, 93(17):1344-1346.
• [60]Schroen AT, Brenin DR, Kelly MD, Knaus WA, Slingluff CL Jr: Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients. J Clin Oncol 2005, 23(28):7074-7080.
• [61]Lazovich D, Solomon CC, Thomas DB, Moe RE, White E: Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer 1999, 86(4):628-637.
• [62]Whelan TJ, Lada BM, Laukkanen E, Perera FE, Shelley WE, Levine MN: Breast irradiation in women with early stage invasive breast cancer following breast conservation surgery. Provincial Breast Disease Site Group. Cancer Prev Control 1997, 1(3):228-240.
• [63]Kong W, Zhang-Salomons J, Hanna TP, Mackillop WJ: A population-based study of the fractionation of palliative radiotherapy for bone metastasis in Ontario. Int J Radiat Oncol Biol Phys 2007, 69(4):1209-1217.
• [64]Penchansky R, Thomas JW: The concept of access: definition and relationship to consumer satisfaction. Med Care 1981, 19(2):127-140.
• [65]Quan ML, Hodgson N, Lovrics P, Porter GA, Poirier B, Wright FC: National adoption of sentinel node biopsy for breast cancer: lessons learned from the Canadian experience. Breast J 2008, 14(5):421-427.
• [66]Wright FC, Gagliardi AR, Fraser N, Quan ML: Adoption of surgical innovations: factors influencing use of sentinel lymph node biopsy for breast cancer. Surg Innov 2011, 18(4):379-386.
• [67]Winget M, Stanger T, Gao Z, Butts C: Predictors of surgery and consult with an oncologist for adjuvant chemotherapy in early stage NSCLC patients in Alberta, Canada. J Thorac Oncol 2009, 4(5):629-634.
• [68]World Health Organization: Bridging the “know-do” gap. Meeting on knowledge translation in global health. World Health Organization, Geneva, Switzerland; 2006.
• [69]Canadian Cancer Control Strategy: Canadian Strategy for Cancer Control. Draft Synthesis Report. Canadian Cancer Control Strategy, Ottawa, ON; 2001.
• [70]Graham ID, Logan J, Harrison MB, Straus SE, Tetroe J, Caswell W, Robinson N: Lost in knowledge translation: time for a map? J Contin Educ Health Prof 2006, 26(1):13-24.
• [71]Porter GA, Urquhart R, Bu J, Johnson PJ, Grunfeld E: Improving nodal harvest in colorectal cancer: So What? Ann Surg Oncol 2011, 18(1):S35.
• [72]Porter GA, Urquhart R, Bu J, McConnell YJ, Grunfeld E: Timely access and quality of care in colorectal cancer: A population-based analysis. Ann Surg Oncol 2010, 17(Suppl 1):S118.
• [73]Urquhart R, Bu J, Porter GA, Dewar R, Moineddin R, Grunfeld E: Relationship between survival and lymph node assessment from a population-based study of colorectal cancer patients. J Clin Oncol 2010., 28(15)
• [74]Urquhart R, Grunfeld E: Building tools to measure and improve access to and quality of colorectal cancer care in Nova Scota. Can J Gastroenterol 2010, 24(Suppl A):91A.
• [75]Urquhart R, Grunfeld E, Porter GA: Synoptic reporting and the quality of cancer care: a review of evidence and Canadian initiatives. Oncology Exchange 2009, 8(1):28-31.
• [76]Johnson PM, Malatjalian D, Porter GA: Adequacy of nodal harvest in colorectal cancer: a consecutive cohort study. J Gastrointest Surg 2002, 6(6):883-888.
• [77]Johnson PM, Porter GA, Ricciardi R, Baxter NN: Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol 2006, 24(22):3570-3575.
• [78]Folkes A, Urquhart R, Zitzelsberger L, Grunfeld E: Breast cancer guidlelines in Canada: a review of development and implementation. Breast Care (Basel) 2008, 3(2):108-113.
• [79]Grunfeld E, Zitzelsberger L, Hayter C, Berman N, Cameron R, Evans WK, Stern H: The role of knowledge translation for cancer control in Canada. Chron Dis Can 2004, 25(2):1-6.
• [80]Daigle R, Urquhart R, Cox M, Grunfeld E, Porter GA: A population-based study of emergency room presentation in colorectal cancer. Can J Surg 2010, 53(4):S65-S66. Canadian Surgery Forum meeting abstracts
• [81]Urquhart R, Folkes A, Porter G, Kendell C, Cox M, Dewar R, Grunfeld E: Population-based longitudinal study of follow-up care for colorectal cancer patients in Nova Scotia. J Oncol Pract 2012, 8(4):246-252.
• [82]Urquhart R, Porter G, Grunfeld E: Reflections on knowledge brokering within a multidisciplinary research team. J Contin Educ Health Prof 2011, 31(4):283-290.
• [83]Raby B, Pater J, Mackillop WJ: Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol 1995, 13(8):1904-1911.
• [84]Mackillop WJ: Health services research in radiation oncology: Towards achieving the cchievable for patients with cancer. In Clinical Radiation Oncology. 2nd edition. Edited by Gunderson LL, Tepper JE. Churchill Livingstone, Philadelphia, PA; 2006.
• [85]Hammersley M: What’s wrong with ethnography?: methodological explorations. Routledge, London; 1992.
• [86]Rice PL: In quality we trust!: the role of qualitative data in health care. Med Principles and Practice 1996, 5:51-57.
• [87]Patton MQ: Qualitative research & evaluation methods. 3rd edition. SAGE Publications, Thousand Oaks, CA; 2002.
• [88]Rice PL, Ezzy D: Qualitative research methods: a health focus. Oxford University Press, Oxford; 1999.
• [89]Strauss AL, Corbin JM: Basics of qualitative research: grounded theory procedures and techniques. Sage, Thousand Oaks, CA; 1990.
• [90]Gerson E: Supplementing grounded theory. In Social Organization and Social Process. Edited by Maines D. Aldine de Gruyter, New York; 1991.
• [91]Rubin H, Rubin I: Qualitative interviewing: the art of hearing data. Sage Publications, Thousand Oaks, CA; 1995.
• [92]Richardson DP, Porter GA, Johnson PM: Surgeon knowledge is associated with clinical and oncologic outcomes in patients with rectal cancer. Ann Surg Oncol 2011, 18(Suppl 1):S102.
• [93]Rogers SO Jr, Ayanian JZ, Ko CY, Kahn KL, Zaslavsky AM, Sandler RS, Keating NL: Surgeons’ volume of colorectal cancer procedures and collaborative decision-making about adjuvant therapies. Ann Surg 2009, 250(6):895-900.